Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Pharmacogenetics
- Factors implicated in PGx phenotypes modulation
- Genetic factors and PGx phenotype variability
- Different study designs provide PGx information
- Genetic epidemiology
- Familial aggregation studies
- Familial resemblance - examples
- Twin and adoption studies
- Response to psychotropic drugs and heterogeneity
- Psychotropic drugs and heterogeneity - example
- PGx - a dynamic approach for behavioral genetics
- Pharmaco-epidemiology and PGx phenotypes
- Animal models
- Conclusion (1)
- Epidemiological evidence and methodology
- Epidemiological evidence and biological pertinence
- PGx phenotypes associated with better detectance
- Different behaviors
- Gene regulation of behavior
- The effect of the same gene differs between subjects
- Drug effect on gene modulation of behavior (1)
- Drug effect on gene modulation of behavior (2)
- Important factors to consider
- Factors related to study design
- Family based vs. case - control design
- Placebo issues
- Assessment issues
- Observer effects
- Sampling bias and PGx
- Epidemiological issues of recruitment
- Example: TD and severity of illness
- Factors related to the subject
- Adherence to treatment
- Duration of illness
- Age and Age at onset of the illness
- Gender
- Comorbid disorders
- Factors related to other treatments of the patient
- History of previous exposure to medications
- Duration of untreated illness
- Concomitant medication
- Diet and smoking
- First episode patients and pharmacogenetics
- Conclusion (2)
- Conclusion (3)
Topics Covered
- Definition of pharmacogenetics (PGx), pharmacokinetics and pharmacodynamics
- Modulation of PGx phenotypes
- Genetic factors play a role in determining the variability of PGx phenotypes
- Study design
- Genetic epidemiology
- Familial aggregation studies
- Twin and adoption studies
- Therapeutic response to psychotropic drugs
- Pharmaco-epidemiology and PGx phenotypes
- Animal models
- Balancing modest epidemiological evidence against biological pertinence
- Studying PGx phenotypes in relation to candidate genes
- Family-based vs. case control designs
- Observer effect
- Sampling bias
- Factors related to the subject
Links
Series:
Categories:
Talk Citation
Joober, R. (2007, October 1). Genetic, environmental and other design issues relevant for pharmacogenetics studies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/NMFU7892.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Ridha Joober has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Genetic, environmental and other design issues relevant for pharmacogenetics studies
A selection of talks on Genetics & Epigenetics
Hide